Response assessment criteria for brain metastases: proposal from the RANO groupNancy U. Lin, Patrick Y. Wen, Michael A. Vogelbaum et al.|The Lancet Oncology|2015Cited by 1.1k
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion studyUdai Banerji, Philippe Aftimos, Carla M.L. van Herpen et al.|The Lancet Oncology|2019Cited by 564
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensusGiuseppe Curigliano, Uwe G. Liebert, Susana Banerjee et al.|Annals of Oncology|2020Cited by 313
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast CancerSjoerd Rodenhuis, Elisabeth G.E. de Vries, M. Bontenbal et al.|New England Journal of Medicine|2003Cited by 262
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumoursF. Eskens, Elisabeth G.E. de Vries|British Journal of Cancer|2007Cited by 231